Immune-Onc Therapeutics Announces Close Of Series B Extension Financing, Bringing Total Round To $131 Million
Round Type
Series B
Palo AltoBiotechnologyHealth CareTherapeuticsInvestors
Description
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints today announced the close of an additional $25 million through a Series B extension, for a total of $131 million in Series B financing. This extension was led by existing investor Triwise Capital and with participation from new investors including Proxima Ventures, among others. In addition, the company has received continued strategic capital investments from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP) and Wuxi Biologics HealthCare Venture.
Quick answer
Immune-Onc Therapeutics raised an undisclosed amount in a Series B round, dated January 5, 2023. Investors: Wuxi Biologics Health Care Venture, Proxima Ventures and Triwise Capital. Immune-Onc Therapeutics is based in Palo Alto, California, United States.
- How much did Immune-Onc Therapeutics raise?
- Immune-Onc Therapeutics raised an undisclosed amount in a Series B round on January 5, 2023.
- Who invested in Immune-Onc Therapeutics?
- Wuxi Biologics Health Care Venture, Proxima Ventures and Triwise Capital are named as investors in this round.
- What does Immune-Onc Therapeutics do?
- Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.
- Where is Immune-Onc Therapeutics based and how big is it?
- Immune-Onc Therapeutics is based in Palo Alto, California, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Immune-Onc Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Pathos AI raised $20M on February 17, 2023.
- Alpha Cognition raised $1.8M (Seed) on February 16, 2023.
- Disc raised $63M (Funding Round) on February 14, 2023.
- Provention Bio raised $35M on February 13, 2023.
- Cerevance raised an undisclosed amount (Series B) on February 13, 2023.
- Chroma Medicine raised $135M on February 8, 2023.
Who to call at Immune-Onc Therapeutics, and when
A new round usually means Immune-Onc Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Immune-Onc Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immune-Onc Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immune-Onc Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immune-Onc Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansImmune-Onc Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.